Literature DB >> 21947717

A case of unsuccessful treatment of heparin-induced thrombocytopenia (HIT) with fondaparinux.

Aimon C Miranda1, Jennifer L Donovan, Maichi T Tran, Joel M Gore.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a rare immune-mediated complication associated with unfractionated heparin and to a lesser extent with low-molecular weight heparins. The American College of Chest Physicians recommends treating patients with suspected HIT with a non-heparin product regardless if thrombosis is present. The direct thrombin inhibitors are the preferred agents for the treatment of acute HIT (lepirudin, argatroban [Grade 1C]). Fondaparinux is also suggested as an alternative with a lower level of evidence (Grade 2C). The evidence supporting the use of fondaparinux in the treatment of HIT is limited, but the evidence of fondaparinux causing HIT is even less. We present a case of a patient who developed complications with fondaparinux when used in the acute setting of HIT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21947717     DOI: 10.1007/s11239-011-0641-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  5 in total

1.  Heparin-induced thrombocytopenia associated with fondaparinux.

Authors:  Theodore E Warkentin; Brian T Maurer; Richard H Aster
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

2.  Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.

Authors:  Khalid A Alsaleh; Sami M A Al-Nasser; Shannon M Bates; Ameen Patel; Theodore E Warkentin; Donald M Arnold
Journal:  Am J Hematol       Date:  2008-11       Impact factor: 10.047

3.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Theodore E Warkentin; Andreas Greinacher; Andreas Koster; A Michael Lincoff
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 4.  Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.

Authors:  Allison Beck Blackmer; Maryann D Oertel; John M Valgus
Journal:  Ann Pharmacother       Date:  2009-09-08       Impact factor: 3.154

5.  Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT).

Authors:  Eugenia Rota; Mario Bazzan; Giovanni Fantino
Journal:  Thromb Haemost       Date:  2008-04       Impact factor: 5.249

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.